Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans.

Autor: Sit SY; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Chen Y; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Chen J; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Venables BL; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Swidorski JJ; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Xu L; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Sin N; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Hartz RA; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Lin Z; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Zhang S; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Li Z; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Wu DR; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Li P; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Kempson J; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Hou X; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Shanmugam Y; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Parker D; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Jenkins S; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Simmermacher J; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Falk P; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., McAuliffe B; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Cockett M; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Hanumegowda U; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Dicker I; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States., Krystal M; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States., Meanwell NA; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States., Regueiro-Ren A; Departments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.; Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2024 Oct 17; Vol. 15 (11), pp. 1997-2004. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024).

The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.

Autor: Regueiro-Ren A; Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Princeton, New Jersey08543, United States., Sit SY; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Chen Y; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Chen J; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Swidorski JJ; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Liu Z; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Venables BL; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Sin N; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Hartz RA; Department of Discovery Chemistry, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Protack T; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Lin Z; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Zhang S; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Li Z; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Wu DR; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Li P; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Kempson J; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Hou X; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Gupta A; Department of Discovery Synthesis; Bristol Myers Squibb Research and Early Development, Bangalore 560099, India., Rampulla R; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Mathur A; Department of Discovery Synthesis, Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey08543, United States., Park H; Bristol Myers Squibb Chemical and Synthetic Development, New Brunswick, New Jersey08901, United States., Sarjeant A; Bristol Myers Squibb Chemical and Synthetic Development, New Brunswick, New Jersey08901, United States., Benitex Y; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Rahematpura S; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Parker D; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Phillips T; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Haskell R; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Jenkins S; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Santone KS; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Cockett M; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Hanumegowda U; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Dicker I; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States., Meanwell NA; Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Princeton, New Jersey08543, United States., Krystal M; Department of Virology, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut06492, United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Sep 22; Vol. 65 (18), pp. 11927-11948. Date of Electronic Publication: 2022 Aug 31.

P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.

Autor: Venables BL; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: brian.venables@bms.com., Sin N; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Wang AX; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Sun LQ; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Tu Y; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Hernandez D; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Sheaffer A; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Lee M; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Dunaj C; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Zhai G; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Barry D; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Friborg J; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Yu F; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Knipe J; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Sandquist J; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Falk P; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Parker D; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Good AC; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Rajamani R; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., McPhee F; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Meanwell NA; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Scola PM; Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Jun 01; Vol. 28 (10), pp. 1853-1859. Date of Electronic Publication: 2018 Apr 05.